Integra LifeSciences Holdings Corporation provided earnings guidance for the year 2018. For the year, the company expected sales at about $1.47 billion, 65% of sales coming from Codman Specialty Surgical business, which is primary neurosurgical procedures and then 35% from Orthopedics and Tissue business, small bones, orthopedics as well as a broad array of tissue reconstruction and Regenerative Technologies. The guidance here that the company communicated at roughly 5% growth in 2018 and 23% to 24% EBITDA and EPS growth of 22% to 27%, heavily tied to kind of core organic but also the contribution from the acquisitions.